• Reported GAAP EPS of -$4.42 down -111.55% YoY • Reported revenue of $0.02M up 175.00% YoY
Bullish
Lucid Diagnostics recognized $1.3M in EsoGuard revenue from 3,177 tests and strengthened its balance sheet with $45M proforma cash. The company also gained strong market presence at DDW with upcoming guideline recommendations.
Bearish
Lucid Diagnostics reported a GAAP net loss of $23.6M and a non-GAAP adjusted loss of $10.5M in Q1 2026. Cash and cash equivalents decreased, and securing Medicare coverage remains a critical pending milestone for the company.